10-Q: HealthLynked Q3: Losses Narrow Amid Revenue Decline, Liquidity Concerns

HealthLynked Corp. reported a narrower net loss in Q3 2025 due to aggressive cost-cutting, despite significant revenue declines across all divisions and ongoing substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for Q3 2025 decreased by 57% to $851,800, compared to $1,973,119 in Q3 2024.
• Net loss for the nine months ended September 30, 2025, decreased by 47% to $2,603,777, compared to $4,901,273 in the same period of 2024.
• Total revenue for Q3 2025 was $388,545, a 34% decrease from $590,124 in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, was $1,755,113, a 27% decrease from $2,389,434 in the same period of 2024.
• Cash balance as of September 30, 2025, was $10,911, down from $76,241 at December 31, 2024.
• Working capital deficit was $5,201,336 and accumulated deficit was $50,768,392 as of September 30, 2025.
• A 1-for-100 reverse stock split was effected on September 4, 2025.
• The BTG physical therapy practice was sold in October 2025 for $125,000 cash.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal controls over financial reporting.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with critically low cash, a substantial working capital deficit, and ongoing net losses. While cost-cutting has narrowed losses, revenue continues to decline across all segments, and there is explicit 'substantial doubt' about its ability to continue as a going concern. The reliance on related-party debt and ineffective internal controls further compound the negative outlook.

Positives

• Net loss significantly narrowed by 57% in Q3 2025 and 47% year-to-date, primarily due to aggressive cost reduction efforts.
• Operating expenses and costs decreased substantially across all categories, including practice salaries and benefits (-60% in Q3, -44% YTD), other practice operating expenses (-41% in Q3, -37% YTD), and selling, general and administrative expenses (-21% in Q3, -37% YTD).
• Cash used in operating activities decreased by $1,456,140 (53%) for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company recognized a gain on extinguishment of debt of $85,150 in Q3 2025 and $260,122 YTD 2025, primarily from extending related party notes.
• The sale of the BTG practice in October 2025 for $125,000 cash provides additional liquidity.

Negatives

• Total revenue decreased by 34% in Q3 2025 and 27% year-to-date, driven by declines in patient service revenue, subscription revenue, and product revenue.
• Patient service revenue decreased by 27% in Q3 2025 and 24% YTD 2025, largely due to the discontinuation of the NWC practice and a 21% decrease at the NCFM practice.
• Subscription revenue plummeted by 96% in Q3 2025 and 62% YTD 2025.
• Product revenue decreased by 82% in Q3 2025 and 66% YTD 2025 due to decreased marketing efforts and demand.
• The company has a severe liquidity issue with a cash balance of only $10,911 and a working capital deficit of $5,201,336 as of September 30, 2025.
• An accumulated deficit of $50,768,392 indicates significant historical losses.
• Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal controls over financial reporting.
• Significant reliance on related party financing from CEO Dr. Michael Dent, with convertible notes payable to him totaling $4,745,472 as of September 30, 2025.
• Incurred a loss on termination of a headquarters lease of $30,146 in the nine months ended September 30, 2025.
• Interest expense increased by 105% for the nine months ended September 30, 2025, due to increased interest-bearing notes payable.

Risks

• Substantial doubt about the company's ability to continue as a going concern through November 19, 2026, without additional funding.
• Uncertainty related to product development and generation of revenues and positive cash flow from the Digital Healthcare Division.
• Dependence on outside sources of capital to fund growth and operating activities.
• Material weaknesses in internal controls over financial reporting, leading to ineffective disclosure controls and procedures.
• Concentration of credit risk in cash and accounts receivable, though no single customer represents 10% or more of revenue.
• Reliance on a sole supplier for approximately 98% of product sales through the Medical Distribution Division (MOD).
• Uncertainty and disruption in the global economy due to geopolitical events (Hamas-Israel, Iran-Israel, Russia-Ukraine conflicts), though no direct material adverse impact yet.
• Litigation risk in the ordinary course of business, which could harm the business.

Future Outlook

The company plans to profitably operate its Health Services business and continue investing in its Digital Healthcare business, the HealthLynked Network, by targeting large health systems, hospitals, and universities, and expanding marketing efforts. It also intends to leverage its Medical Distribution subsidiary, MOD, for patient and physician members. Future growth and profitability are dependent on obtaining adequate financing and successfully marketing the HealthLynked Network.

Management Comments

• Without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were issued (November 19, 2026).
• We expect to continue to incur net losses and have significant cash outflows for at least the next 12 months.
• Our plan of operations is to profitably operate our Health Services business and continue to invest in our Digital Healthcare business, including our cloud-based online personal medical information and record archiving system, the HealthLynked Network.
• If we fail to complete the development of, or successfully market, the HealthLynked Network, our ability to realize future increases in revenue and operating profits could be impacted, and our results of operations and financial position would be materially adversely affected.

Industry Context

The company operates in the fragmented healthcare services, digital health, and medical distribution sectors. Its strategy of consolidating physical practices and developing a digital health network (HealthLynked Network) aligns with broader industry trends towards integrated care and digital transformation. However, the significant revenue declines in both traditional health services and digital subscriptions suggest challenges in market penetration and competitive positioning, especially given the intense competition and capital requirements in these areas. The reliance on a single supplier for medical distribution also highlights a vulnerability in its supply chain.

Comparison to Industry Standards

• The company's significant accumulated deficit of over $50 million and ongoing net losses are substantially worse than industry benchmarks for profitable, growing healthcare companies.
• A cash balance of $10,911 and a working capital deficit of over $5.2 million indicate severe liquidity issues, far below healthy industry standards for operational stability.
• The heavy reliance on related-party debt from the CEO for ongoing operations is atypical and generally viewed negatively compared to companies with diversified funding sources.
• The 1-for-100 reverse stock split, while a corporate action, often signals a company struggling with low stock prices and can be a negative indicator compared to peers with stable or appreciating stock values.
• The disclosure of ineffective internal controls over financial reporting is a significant governance red flag, contrasting sharply with the robust control environments expected of publicly traded companies.

Corporate Governance

Legal Proceedings

• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business.
• Management is not aware of any current legal proceedings that will have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• Significant reliance on Dr. Michael Dent (CEO and Chairman) for financing, including convertible notes payable and undocumented cash advances.
• As of September 30, 2025, $5,216,072 was owed to Dr. Michael Dent, including convertible notes payable carried at fair value ($4,235,519), amortized value ($509,953), undocumented advances ($170,000), and deferred compensation ($300,600).
• Maturity dates on multiple notes payable to Dr. Dent were extended in March, June, and September 2025, in exchange for warrants to purchase common stock.
• Issued several new convertible notes payable to a trust controlled by Dr. Michael Dent in July, September, and October 2025.
• Dr. Dent's employment agreement includes severance provisions if terminated without cause.

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future capital raises and conversion of convertible notes. The reverse stock split may temporarily boost share price but doesn't address underlying financial issues. The "going concern" warning indicates a high risk of investment loss.
• Employees: Cost reduction efforts have led to changes in clinical staffing and corporate overhead, potentially impacting job security and morale.
• Customers (Patients/Practices): Discontinuation of NWC practice and sale of BTG practice impact service availability. Consolidation of practices may affect patient experience.
• Suppliers: The company's precarious financial position and reliance on a single supplier for MOD sales could pose risks to supplier relationships and payment terms.
• Creditors: High risk due to the company's substantial debt, working capital deficit, and going concern uncertainty. Related-party debt from the CEO may have different terms than third-party debt.

Next Steps

• Successfully market the HealthLynked Network to large health systems, hospitals, and universities.
• Expand direct-to-patient and affiliated marketing campaigns for the HealthLynked Network.
• Leverage MOD's discounted medical supplies for HealthLynked Network members.
• Hire physician telesales representatives as access to capital allows.
• Raise additional capital through equity or debt instruments, including the Regulation A Offering.
• Address material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company is in a highly precarious financial position, explicitly stating 'substantial doubt about its ability to continue as a going concern' within the next 12 months. Revenue is declining across all segments, cash reserves are critically low ($10,911), and the working capital deficit is significant ($5.2 million). While cost-cutting has narrowed net losses, it has not stemmed the revenue decline or addressed the fundamental liquidity crisis. The heavy reliance on related-party debt from the CEO and the disclosure of ineffective internal controls are major red flags. The recent reverse stock split is often a sign of distress. Without a clear path to sustainable profitability and significant external capital, the risk of further value erosion or bankruptcy is extremely high.

Keywords

HealthLynked Corp, HLTH, SEC 10-Q, Quarterly Report, Healthcare Services, Digital Healthcare, Medical Distribution, Financial Results, Net Loss, Revenue Decline, Cost Reduction, Going Concern, Liquidity, Reverse Stock Split, Related Party Debt, Corporate Governance, Internal Controls, Medical Records, Telemedicine, Medical Supplies